Price List - Redemplo - Antilipidemics-2 - NA.xlsx

XLSX spreadsheet 46 KB Posted

Attached to
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9103
Issued by

About this file

This Excel file is a Price List for the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee's February 2026 Uniform Formulary (UF) review, specifically for the Antilipidemics-2 drug class. The document contains Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) appendices for up to 10 newly approved drugs, with quotes due on January 5, 2026, for the February 4-5, 2026 P&T Committee meeting.

The file includes detailed pricing and formulary scenarios for potential drug tiers (Uniform Formulary, Non-Formulary, Tier 2, Tier 3), with provisions for pricing calculations using non-Federal Average Manufacturer Price (non-FAMP) and Wholesale Acquisition Cost (WAC) methodologies. The document emphasizes potential prior authorization requirements, step therapy protocols, and the P&T Committee's ability to recommend preferential status, tier designations, or potential exclusion from the TRICARE pharmacy benefit program. Manufacturers are instructed to submit fully executed signature pages with quote information, with pricing to be consistent across package sizes and dispensing venues.

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the February 2026 DoD P&T Meeting
DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 1262ALNAG1UF1MUniform Formulary1 or moreNO QUOTE
262ALNAG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the February 2026 DoD P&T Meeting
DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

ADP (WAC Discount)

UF ADP Appendix for the February 2026 DoD P&T Meeting
DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DOD Uniform Formulary Class:ANTILIPIDEMICS-2P&T Committee Meeting:February 4-5, 2026
DOD Uniform Formulary Subclass:N/AQuotes due:January 5, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 1262ALNAG1T21MTier 21 or more
262ALNAG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .